Phacolysine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H596224

CAS#: 3863-80-7

Description: Phacolysine is a chemical used in ophthalmologic eye lotions.

Chemical Structure

img
Phacolysine
CAS# 3863-80-7
Instruction

Theoretical Analysis

Hodoodo Cat#: H596224
Name: Phacolysine
CAS#: 3863-80-7
Chemical Formula: C18H10N4Na2O6S2
Exact Mass: 0.00
Molecular Weight: 488.400
Elemental Analysis: C, 44.27; H, 2.06; N, 11.47; Na, 9.41; O, 19.65; S, 13.13

Price and Availability

Size Price Availability Quantity
10mg USD 540 2 Weeks
Bulk inquiry

Synonym: Phacolysine; Quinax; Azapentacene; Jing Ming;

IUPAC/Chemical Name: sodium 5,12-dihydroquinoxalino[2,3-b]phenazine-2,9-disulfonate

InChi Key: XLNKBYYWZULHIR-UHFFFAOYSA-L

InChi Code: InChI=1S/C18H12N4O6S2.2Na/c23-29(24,25)9-1-3-11-13(5-9)21-17-8-16-18(7-15(17)19-11)22-14-6-10(30(26,27)28)2-4-12(14)20-16;;/h1-8,19-20H,(H,23,24,25)(H,26,27,28);;/q;2*+1/p-2

SMILES Code: [O-]S(c1cc(N=c2c(N3)cc4c(Nc5c(N=4)cc(S([O-])(=O)=O)cc5)c2)c3cc1)(=O)=O.[Na+].[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 488.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yu X, Liao Z, Yao Q, Liu H, Xie W. Spectroscopic studies on the interaction of Phacolysin and bovine serum albumin. Spectrochim Acta A Mol Biomol Spectrosc. 2014 Jun 5;127:231-6. doi: 10.1016/j.saa.2014.02.064. Epub 2014 Feb 27. PubMed PMID: 24632176.

2: Shvachko AG, Formaziuk VE, Sergienko VI. [Chemiluminescence decrease of singlet oxygen in NaClO+H2O2 reaction in the presence of different anti-cataract drugs]. Biull Eksp Biol Med. 1991 Jul;112(7):42-4. Russian. PubMed PMID: 1793850.

3: Maĭchuk IuF, Bazukina LP, Orlovskaia LE, Lapshina NA, Khaitova KN, Iakushina LN. [Use of phacolin in patients with allergic reaction to anti-cataract eye drops]. Vestn Oftalmol. 1991 May-Jun;107(3):68-71. Russian. PubMed PMID: 1755171.

4: Svachko AG, Formaziuk VE, Sergienko VI. [Decrease of singlet oxygen chemiluminescence by the presence of carnosine]. Biull Eksp Biol Med. 1990 Aug;110(8):155-7. Russian. PubMed PMID: 2291961.

5: Stankiewicz A, Poppe E, Stasiewicz B, Gołebiowska-Hrycukowa A. [Evaluation of the effectiveness of Quinax in the prevention of the development of senile cataract]. Klin Oczna. 1990 Aug;92(3-4):52-4. Polish. PubMed PMID: 2263035.

6: Chasovnikova LV, Formazyuk VE, Sergienko VI, Boldyrev AA, Severin SE. The antioxidative properties of carnosine and other drugs. Biochem Int. 1990;20(6):1097-103. PubMed PMID: 2369412.

7: Popa DP, Vasinca D. [Treatment of cataract with Quinax]. Rev Chir Oncol Radiol O R L Oftalmol Stomatol Ser Oftalmol. 1988 Oct-Dec;32(4):273-8. Romanian. PubMed PMID: 2978086.

8: Mal'tsev EV. [Conservative treatment of cataract]. Oftalmol Zh. 1984;(7):430-4. Review. Russian. PubMed PMID: 6396559.

9: Zygulska-Mach H, Pioruńska M, Paziewski E. [Use of the preparation quinax in the trial treatment of senile and secondary cataract]. Wiad Lek. 1982 Nov 1;35(19-20):1239-43. Polish. PubMed PMID: 6761971.

10: Prost M, Toczołowski J. [Clinical evaluation of the inhibitory effect of Quinax on the progression of senile cataract]. Klin Oczna. 1982 Mar;84(3):71-2. Polish. PubMed PMID: 6757553.

11: Eyada KA. Metabolism of cataract and medical treatment. Metab Pediatr Ophthalmol. 1981;5(2):99-103. PubMed PMID: 7289691.

12: Fukushi S, Suzuki T. [Studies on azapentacene, anti-cataract agent (author's transl)]. Nippon Ganka Gakkai Zasshi. 1981 Jan;85(1):37-43. Japanese. PubMed PMID: 7258001.

13: Jabłoński J, Pankowska B. [Quinax preparation in conservative treatment of senile cataract (author's transl)]. Klin Oczna. 1980 Apr;82(4):219-20. Polish. PubMed PMID: 7431800.

14: FUJIYAMA H, SAKAI C, TANAKA N, NARA N, FUTAGAMI S, ADACHI H. [Treatment of cataracta congenita, traumatica and complicata with the eye-lotion "Phacolin"]. Rinsho Ganka. 1962 Apr;16:389-93. Japanese. PubMed PMID: 13895779.